| Literature DB >> 1826127 |
H R Alexander1, G M Doherty, C M Buresh, D J Venzon, J A Norton.
Abstract
Interleukin 1 (IL-1) is an endogenously produced cytokine that mediates a variety of physiological effects that may be beneficial or deleterious to the host. C57Bl/6 mice treated intravenously with a recently characterized human recombinant receptor antagonist protein to IL-1 (IL-1ra) had improved survival when treated after a lethal Escherichia coli endotoxin (lipopolysaccharide [LPS]) challenge. IL-1ra was effective when treatment was initiated after LPS, and intravenous administration every 4 h for 24 h was required. Serum levels of tumor necrosis factor (TNF) activity after LPS and in vitro TNF cytotoxicity were not altered by treatment with IL-1ra. These experiments provide direct evidence that the lethal effects of LPS may be mediated through the action of IL-1 and that the IL-1ra can provide a new treatment strategy for disease processes mediated via this cytokine.Entities:
Mesh：
Substances：
Year: 1991 PMID： 1826127 PMCID： PMC2190820 DOI： 10.1084/jem.173.4.1029
Source DB: PubMed Journal: J Exp Med ISSN： 0022-1007 Impact factor: 14.307